Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
Launched by BRISTOL-MYERS SQUIBB · Aug 9, 2024
Trial Information
Current as of September 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how patients with a heart condition called obstructive hypertrophic cardiomyopathy (HCM) feel after being treated with a medication called mavacamten. The study aims to understand the real-life effects of this treatment on the health and daily lives of those who experience symptoms from their condition. If you are at least 18 years old, have been prescribed mavacamten for HCM, and are willing to participate, you may be eligible to join the trial.
Participants in the study will provide feedback on their health status through surveys. It's important to note that those who have recently participated in other clinical trials for heart medications, or who have had major health events like heart attacks or strokes, may not be able to join. This study is currently recruiting participants, and it will help researchers learn more about how well mavacamten works for patients in everyday settings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants ≥18 years of age.
- • Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy
- • Provided informed consent to participate in the study
- Exclusion Criteria:
- • Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors
- • Treated for \>7 days with mavacamten by the day of completing the baseline survey
- • Enrolled in any clinical trials at the time of or within the six-month period prior to the screening
- • Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the screening
- • Had stroke or transient ischemic attack within the six-month period prior to the screening
- • Had moderate-to-severe lung disease which impacted the ability to perform daily activities of living and ability to breathe
- • Had major lung (thoracic) or heart (cardiac) surgery within the six-month period prior to the screening
- • Scheduled for a major surgery for the next three months, such as joint surgeries including hip replacement, abdominal surgeries, lung surgeries, heart surgeries, eye surgeries, brain surgeries, and any other major surgeries that require general anesthesia and at least an overnight hospital stay
- • Hospitalized requiring an overnight stay at the time of or within the two-week period prior to the screening
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported